The patent litigation team of this national full-service firm is one of the challengers to the French market leaders in patent litigation. With its firmly established team of partners, the practice covers a wide spectrum of work in the French part of international patent cases. It has a pronounced strength in life sciences litigation. In this sector, such major players as BMS and Genentech trust in the team, which is also present in the ongoing important issues, such as SPCs, as well as in biotech suits. Gide Loyrette Nouel is, however, seen less often in high-profile telecommunications proceedings than competitors such as Allen & Overy.
The firm prepared for the departure of senior litigator Grégoire Triet a long time in advance. Along with the move of Arnaud Michel this creates space for up-and-coming lawyers in the team. A counsel appointment underscores the ambitions of the practice, led by the well-established Raphaëlle Dequiré-Portier, to grow sustainably.
The patent practice uses its interface with the antitrust practice to conduct joint proceedings before the European Commission. This competence sets it apart from national competitors like Loyer & Abello.
Representation of originator and generic drugs manufacturers in pharmaceutical cases.
Gide Loyrette Nouel has many years of experience litigating in the French part of international patent proceedings. For these cases, the team is trusted by numerous pharma companies and medical product manufacturers. The patent practice frequently works in cooperation with national IP boutiques, including Arnold Ruess in Germany, or national full-service firms, such as Gleiss Lutz. In suits before the UPC, the firm will have to compete with internationally-integrated firms to win over its clients with this experience. Although Gide has its own offices in London and Brussels, the firm does not advise on IP from these locations.
Jean-Hyacinthe de Mitry (“high-quality litigator”, competitor), Raphaëlle Dequiré-Portier (“experienced and really good”, competitor), Emmanuel Larere
Arnaud Michel (to Dorean), Grégoire Triet (to Taliens)
Strong focus on patent litigation, especially pharma, biotech and life sciences. Strategic advice on trade secrets, including seizures (saisie-contrefaçon).
Litigation: Beckman Coulter (defendant) against Brahms in infringement case with product seizures over blood testing for sepsis; BMS (defendant) against Teva over SPC; Celltrion (claimant) against Biogen, Genentech and Hoffmann-La Roche over cancer drug; Genmab (claimant) over SPC for daratumumab; Guerbet (defendant) against Bayer over medical imaging (Court of Appeal); Meril (defendant) against Edwards Lifesciences over heart valves; Ono Pharmaceutical and BMS (claimant) against INPI on SPCs for immunotherapy treatments (Supreme Court); Sanofi-Aventis (claimant) against Mylan over pen syringe for injecting a biosimilar of Lantus (Court of Appeal); Teoxane (defendant) against Vivacy over dermal fillers; KDE (claimant) against Belmoca and Sodastream France over aluminium coffee capsules; U-Shin (claimant) against competitor Akwel over a car door opening device provided to PSA; WSOU (claimant) against Huawei over mobile communications (settled in 2021); WSOU (claimant) against ZTE over mobile communications. Frequent advice to Avril, Johnson & Johnson, Haulotte, Mnemo Therapeutics.